In recent days, concern over a global outbreak of monkeypox, a mild disease related to smallpox and chickenpox, has been hyped in the media and health ministries around the world, even prompting an emergency meeting at the World Health Organization (WHO). For some, fears have centered around monkeypox being the potential “next pandemic” after Covid-19. For others, the fear is that monkeypox will be used as the latest excuse to further advance draconian biosecurity policies and global power grabs.
Regardless of how the monkeypox situation plays out, two companies are already cashing in. As concern over monkeypox has risen, so too have the shares of Emergent Biosolutions and SIGA Technologies. Both companies essentially have monopolies in the US market, and other markets as well, on smallpox vaccines and treatments. Their main smallpox-focused products are, conveniently, also used to protect against or treat monkeypox as well. As a result, the shares of Emergent Biosolutions clim...